Halozyme Therapeutics HALO Available-for-Sale Debt Securities
Available-for-Sale Debt Securities at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's available-for-sale debt securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's available-for-sale debt securities?
- Halozyme Therapeutics (HALO) reported available-for-sale debt securities of $8.87M in Q1 2026.
- How has Halozyme Therapeutics's available-for-sale debt securities changed year-over-year?
- Halozyme Therapeutics's available-for-sale debt securities decreased by 98.4% year-over-year, from $571.59M to $8.87M.
- What is the long-term trend for Halozyme Therapeutics's available-for-sale debt securities?
- Over 3 years (2022 to 2025), Halozyme Therapeutics's available-for-sale debt securities has grown at a -58.8% compound annual growth rate (CAGR), from $128.6M to $9M.
- What does available-for-sale debt securities mean?
- These are debt instruments that the company intends to hold for an indefinite period but may sell if liquidity needs arise. They are reported at fair value on the balance sheet, with unrealized gains or losses recorded in other comprehensive income rather than net income. This metric reflects the company's strategy for managing excess cash reserves through interest-bearing securities.